Ishiwata, Naoko PhD1; Melby, Melissa Okay. PhD2; Mizuno, Shoichi PhD2; Watanabe, Shaw MD, DSc2
From the 1Department of Life Environments Management, Atomi College, Nakano, Niza-shi, Saitama, Japan; and 2National Institute of Well being and Nutrition, Toyama, Shinjyuku-ku, Tokyo, エクオール（及びエクオール サプリ） Japan.
Acquired March 30, 2008; revised and accepted Could 27, 2008.
Monetary support: Otsuka Pharmaceutical Co Ltd, Japan, provided the complement and financial assist.
Monetary disclosure: None reported.
Handle correspondence to: Naoko Ishiwata, PhD, Department of Life Environments Administration, Atomi University, 1-9-6 Nakano, Niza-shi, Saitama 352-8501, Japan. E-mail: [e-mail protected]
Buy
Summary
Goals:
Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a significant position in the well being benefits of soy. We examined the effect of a new S-equol complement on menopausal symptoms and mood states.
Design:
We conducted a randomized, double-blind, placebo-managed trial with our new equol complement for 12 weeks with 134 Japanese ladies (aged 40-fifty nine years). They were randomly assigned to a few groups: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol 3 times per day (EQ-3; n = 46). Habitual isoflavone intake was limited to 20 mg/d. Individuals accomplished menopausal symptom and Profile of Temper States questionnaires at baseline and postintervention. Bodily examination and blood and 24-hour urine assortment had been performed at baseline and postintervention.
Results:
At baseline, whole menopausal symptom score diverse by menopausal and equol producer status (34.3% producers). A total of 127 contributors (94.8%) completed the trial. No hostile results were reported, aside from a systemic rash in a single EQ-three lady. The anxiety scores of equol producers were lower than those of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States.